SEC Tracker
Get the app
XFOR · XBRL financial data

X4 Pharmaceuticals financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (XFOR's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024†Mar 31, 2025†Jun 30, 2025Sep 30, 2025†Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue00*—563560year only9001,7441,5662,200*2,5002,400
Revenue from contracts with customers—year only0700560year only28,8071,9731,7652,568*2,7088,806
Cost of revenue00*0268227302*4,716326351364*5981,617
Research and development19,08115,272*19,85420,91419,17321,702*18,51318,35217,33718,521*15,45015,079
General and administrative8,1339,927*17,43513,27815,66015,145*15,0219,52711,5867,382*6,9668,501
Total operating expenses27,21425,199*37,289—————————
Operating income (loss)(27,214)(25,199)*(37,289)71,103(34,500)(35,715)*(9,443)(26,232)(27,509)(23,699)*(20,306)(16,391)
Interest income1,3881,445*1,0661,5651,8711,267*1,0256659011,985*2,1051,979
Interest expense1,6341,886*1,8742,1762,4142,304*2,2012,2322,2572,186*2,1342,164
Other income (expense)17212*105144226700105(547)(304)(7)*14(107)
Income tax expense (benefit)2633*191815258*3437(30)0*02
Net income (loss)(2,305)(19,130)*(51,766)90,833(36,696)(39,821)*282(25,741)(29,815)(23,925)*(20,241)(16,157)
Earnings per share, basic‡ USD per share(0.30)(3.00)*(7.81)13.51(5.41)(6.01)*1.20(104.20)(20.72)—(0.16)(0.13)
Earnings per share, diluted‡ USD per share(0.30)(3.00)*(7.81)13.51(5.41)(6.01)*1.20(104.20)(20.72)—(0.16)(0.13)
Weighted average shares, basic‡ thousands of shares6,5606,619*6,6606,6756,6896,758*2282471,441—126,289126,344
Weighted average shares, diluted‡ thousands of shares6,5606,619*6,6606,6876,6896,746*2292471,441—126,289126,344
  • ‡ Per-share figures and share counts are adjusted for the 1-for-30.030030030030026 stock split (April 2025); filings made before it reported them unadjusted.
  • † Share count changed about 1/30 in the period ending 2025-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
  • † Share count changed about 2x in the period ending 2025-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
  • † Share count changed about 31x in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Balance sheet

CSV

Fiscal quarters (XFOR's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024†Mar 31, 2025†Jun 30, 2025Sep 30, 2025†Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents131,58199,21660,493147,21897,41255,69940,25739,22069,632217,049216,908195,095
Accounts receivable—0—001,0705091,1458915731,1132,047
Inventory—0———2,817——————
Prepaid and other current assets5,7967,2985,7624,9774,4775,5884,4834,9564,9253,5272,5123,337
Total current assets147,872122,07687,333175,416142,972112,17595,69772,942132,805261,577241,982218,855
Property and equipment, net772745742808820776487254218182146111
Right-of-use asset6,0545,6505,2644,8724,4714,0653,6522,6461,7751,4091,035654
Goodwill17,35117,35117,35117,35117,35117,35117,35117,35117,35117,35117,35117,351
Total assets173,293147,258112,182210,611178,165146,447130,013105,168163,555290,461270,281253,063
Accounts payable8,1328,9478,9357,9868,5778,62111,1157,7095,0535,6965,0733,934
Accrued liabilities16,18412,81613,47319,74419,45923,00512,61113,06516,66118,60317,05514,125
Current portion of long-term debt00——————————
Total current liabilities25,43222,86223,54128,90229,25832,87725,88422,89623,50625,75723,77119,366
Long-term debt—54,570——————————
Lease liability, non-current2,8482,6122,3182,0261,7571,4101,109815950——
Total liabilities105,69996,159111,146116,160118,544124,298107,069101,197101,936104,171101,83197,609
Accumulated deficit(458,775)(477,905)(529,671)(438,838)(475,534)(515,355)(515,073)(540,814)(570,629)(594,554)(614,795)(630,952)
Total stockholders' equity67,59451,0991,03694,45159,62122,14922,9443,97161,619186,290168,450155,454
Total liabilities and equity173,293147,258112,182210,611178,165146,447130,013105,168163,555290,461270,281253,063
Common shares outstanding (cover page)‡ thousands of shares5,5715,5925,5925,6115,6795,7831933802,91290,92094,32099,147
  • ‡ Per-share figures and share counts are adjusted for the 1-for-30.030030030030026 stock split (April 2025); filings made before it reported them unadjusted.
  • † Share count changed about 1/30 in the period ending 2025-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
  • † Share count changed about 2x in the period ending 2025-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
  • † Share count changed about 31x in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Cash flows

CSV

Fiscal quarters (XFOR's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024†Mar 31, 2025†Jun 30, 2025Sep 30, 2025†Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(2,305)(19,130)*(51,766)90,833(36,696)(39,821)*282(25,741)(29,815)(23,925)*(20,241)(16,157)
Stock-based compensation2,361*2,539*1,7392,428*1,820*2,217*519748*760*2,271*2,4133,086*
Depreciation and amortization104*62*62194*267*273*476355*223*223*223997*
Net cash from operating activities(68,800)(27,747)*(33,597)(63,900)(34,032)*(32,995)*(12,368)(29,901)*(27,822)*(15,527)*(19,599)(20,788)*
Purchases of property and equipment—year only———year only——————
Net cash from investing activities(5,157)*(4,833)*(5,322)96,862*(15,929)*(8,621)*(3,138)23,112*(28,669)*16,849*19,252(1,000)*
Proceeds from issuing common stock2*51,384*——0*(159)*——86,905*146,040*——
Share repurchases—year only——————————
Repayments of long-term debt—year only———year only———year only——
Net cash from financing activities21,205*97*020,159*0*135*05,631*86,905*146,092*275*
Net change in cash(4,852)*(32,356)*(38,978)86,726*(49,796)*(41,725)*(15,434)(1,019)*30,413*147,417*(365)(21,718)*
  • † Share count changed about 1/30 in the period ending 2025-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
  • † Share count changed about 2x in the period ending 2025-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
  • † Share count changed about 31x in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Compare with peers

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
X4 Pharmaceuticals195,0952,400(20,788)*99.1M9.4 quarters 10-QJun 30, 2026
Akari Therapeutics7,694not reported(3,109)*155.8B2.5 quarters 10-QJun 30, 2026
ProPhase Labs201,011(78)*15.6M0.3 quarters 10-QJun 30, 2026
Pluri3,529335*(4,443)*12.3M0.8 quarters 10-KJun 30, 2026
CalciMedica18,617not reported(4,620)*34.1M4.0 quarters 10-QJun 30, 2026
Edesa Biotech10,300not reported(3,083)*9.6M3.3 quarters 10-QJun 30, 2026
GeoVax Labs3,143not reported(3,658)*7.4M0.9 quarters 10-QJun 30, 2026
Earth Science Tech6319,026707287.6M— 10-QJun 30, 2026
Lipocine4,979190(3,028)*8.2M7.7 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.